+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Early Phase 1
Age: 18Years - 100Years
All Genders
ID07428707

Study of Immune Effects of First-Line Oral Pirtobrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Led by National Heart, Lung, and Blood Institute (NHLBI) · Updated on 2026-10-22

30

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating pirtobrutinib as a first treatment option for people with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL, which are types of blood cancers that affect white blood cells. This early-phase study aims to understand how pirtobrutinib impacts the immune system in patients who have not received prior treatment for these diseases. The research also looks at the safety and effectiveness of this drug in this population. Participants will take pirtobrutinib orally at a dose of 200 mg once daily in 28-day cycles, continuing until the disease progresses or side effects require stopping treatment. The study includes regular clinic visits every 4 weeks for the first 3 months, then every 3 months thereafter. Procedures include imaging scans, heart function tests, lymph node biopsies, and blood tests at various points. A bone marrow biopsy may be done if no disease is detected after one year. Optional blood collection for cancer and immune cell research is also offered. During the study, participants will undergo detailed assessments including physical exams, blood and tissue sampling, and immune profiling of lymph nodes and peripheral blood. Researchers will measure immune cell changes, tumor cells, and treatment responses. After stopping the drug, participants have a follow-up visit one month later, with additional follow-ups by visits or phone every 6 to 12 months. The total study duration may last several years, allowing long-term monitoring of outcomes and safety.

CONDITIONS

Brief Title

Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib

Research Team

N

NIH Clinical Center Office of Patient Recruitment (OPR)

L

Laura S Samples, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here